Category
page 1Chemical biology
sirolimus
Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumour (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mammalian target of rapamycin (mTOR) kinase inhibitor that reduces the sensitivity of T cells and B cells to interleukin-2 (IL-2), inhibiting their activity.
chemical biology
application of chemical techniques, analysis, and often small molecules produced through synthetic chemistry, to the study and manipulation of biological systems
bioorthogonal chemistry
class of chemical reactions that can occur inside of living systems without interfering with native biochemical processes
protein engineering
biochemical and genetic engineering processes involved in the synthesis, modification, and production of protein products for various applications
Stuart Schreiber
American chemist
proteolysis targeting chimera
small molecule
peptidomimetic
thumbnail|right|300px|Figure 1. Classification of peptidomimetics.|alt=Four peptidomimetics classified (A – D), based on their similarity with the precursor peptide.A peptidomimetic is a small protein-like chain designed to mimic a peptide. They typically arise either from modification of an existing peptide, or by designing similar systems that mimic peptides, such as peptoids and β-peptides. Irrespective of the approach, the altered chemical structure is designed to advantageously adjust the molecular properties such as stability or biological activity. This can have a role in the developmen
chemoproteomics
Chemoproteomics (also known as chemical proteomics) entails a broad array of techniques used to identify and interrogate protein-small molecule interactions. Chemoproteomics complements phenotypic drug discovery, a paradigm that aims to discover lead compounds on the basis of alleviating a disease phenotype, as opposed to target-based drug discovery (reverse pharmacology), in which lead compounds are designed to interact with predetermined disease-driving biological targets. As phenotypic drug discovery assays do not provide confirmation of a compound's mechanism of action, chemoproteomics pro